Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Amplia Therapeutics ( (AU:ATX) ) is now available.
Amplia Therapeutics Limited has successfully raised approximately $22.3 million through the issuance of 96,804,354 fully paid ordinary shares. This capital will support the ongoing development of their lead drug candidate, narmafotinib (AMP945), which is currently undergoing a Phase 2a trial for pancreatic cancer. The ACCENT trial, exploring the efficacy of narmafotinib in combination with standard chemotherapy, aims to provide insights into the drug’s potential benefits for patients with advanced pancreatic cancer. This development underscores Amplia’s commitment to advancing treatment options for fibrotic cancers and enhancing its position in the pharmaceutical industry.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company specializing in the development of Focal Adhesion Kinase (FAK) inhibitors for treating cancer and fibrosis. The company is particularly focused on fibrotic cancers such as pancreatic and ovarian cancer, as well as chronic diseases like idiopathic pulmonary fibrosis (IPF).
Average Trading Volume: 6,873,508
Technical Sentiment Signal: Buy
Current Market Cap: A$95.47M
See more insights into ATX stock on TipRanks’ Stock Analysis page.